Program Schedule

418
Antimicrobial Profile of Enterobacteriaceae from North America from 2013

Session: Poster Abstract Session: Surveillance of Antimicrobial Resistance
Thursday, October 9, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC

Background: Enterobacteriaceae play an important role in the pathogenesis of hospital infections worldwide. The Tigecycline Evaluation Surveillance Trial (TEST) examines the susceptibility of pathogens isolated from multiple infectious processes from patients in geographically diverse populations. With the increase of antimicrobial resistance, continued surveillance and susceptibility testing of pathogens isolated from patients in North America is essential. The purpose of this report is to examine the susceptibility of selected Enterobacteriaceae species isolated from patients in the United States and Canada from 2013.

Methods:   4,010* clinically significant Enterobacteriaceae sp. were obtained from patients with a wide spectrum of infections in patients in the United States and Canada.  MICs were determined from 30 sites in 2013 using supplied broth microdilution panels. Susceptibility was interpreted according to CLSI guidelines. Results: The % susceptible for those 4,010 gram-negative bacilli against tigecycline and comparative antimicrobial agents is shown in the following table:

 

 

Drug % Susceptible

Organism (N)

AK

AC

CPM

CFT

LEVO

MER

PT

TIG

E. aerogenes (272)

99.3

3.7

98.9

77.6

97.4

98.5

86.0

97.4

E. asburiae (102)

100

5.9

100

80.4

97.1

100

91.2

100

E. cloacae (688)

99.9

4.7

95.6

70.4

93.9

98.6

82.1

94.9

E. coli (1232)

99.8

75.1

91.8

86.7

69.6

98.7

96.1

99.7

K. oxytoca (259)

100

87.6

98.1

90.0

95.0

99.2

91.1

98.8

K. pneumoniae (957)

98.6

85.6

90.9

84.1

86.7

95.2

89.7

95.0

S. marcescens (462)

100

1.5

98.7

85.7

91.6

98.1

96.5

96.3

AK=Amikacin, AC=Amoxicillin-Clavulanate, CPM=Cefepime, CFT=Ceftriaxone, LEVO=Levofloxacin, MER=Meropenem PT=Piperacillin-Tazobactam, TIG=Tigecycline

*n's ≤ 15 are not reported

Conclusion: In vitro tigecycline, meropenem and amikacin continue to be the most active antimicrobials against all Enterobacteriaceae. In the US and Canada the existence of levofloxacin resistant E. coli continues to be an issue. Additional monitoring of antimicrobial resistance in hospital pathogens in North America is warranted.

 

Brian Johnson, BS1, Jack Johnson, MS, MBA1, Samuel Bouchillon, MD1, Daryl Hoban, PhD1, Meredith Hackel, PhD, MPH1, Sibylle Lob, MD, MPH1, Douglas Biedenbach, BS1 and Heidi Leister-Tebbe, BS2, (1)International Health Management Associates, Inc., Schaumburg, IL, (2)Pfizer Inc., Collegeville, PA

Disclosures:

B. Johnson, Pfizer: Independent Contractor, Consulting fee

J. Johnson, Pfizer: Independent Contractor, Consulting fee

S. Bouchillon, Pfizer: Independent Contractor, Consulting fee

D. Hoban, Pfizer: Independent Contractor, Consulting fee

M. Hackel, Pfizer: Independent Contractor, Consulting fee

S. Lob, Pfizer: Independent Contractor, Consulting fee

D. Biedenbach, Pfizer: Independent Contractor, Consulting fee

H. Leister-Tebbe, Pfizer: Employee, Salary

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek